BACKGROUND: It remains uncertain whether acetylcysteine prevents contrast-induced acute kidney injury. METHODS AND RESULTS: We randomly assigned 2308 patients undergoing anintravascular angiographic procedure with at least 1 risk factor for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) toacetylcysteine 1200 mg or placebo. The study drugs were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 12.7% in the acetylcysteine group and 12.7% in the control group (relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; P=0.97). A combined end point of mortality or need for dialysis at 30 days was also similar in both groups (2.2% and 2.3%, respectively; hazard ratio, 0.97; 95% confidence interval, 0.56 to 1.69; P=0.92). Consistent effects were observed in all subgroups analyzed, including those with renal impairment. CONCLUSIONS: In this large randomized trial, we found that acetylcysteine does not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients undergoing coronary and peripheral vascular angiography. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00736866.
RCT Entities:
BACKGROUND: It remains uncertain whether acetylcysteine prevents contrast-induced acute kidney injury. METHODS AND RESULTS: We randomly assigned 2308 patients undergoing an intravascular angiographic procedure with at least 1 risk factor for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) to acetylcysteine 1200 mg or placebo. The study drugs were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 12.7% in the acetylcysteine group and 12.7% in the control group (relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; P=0.97). A combined end point of mortality or need for dialysis at 30 days was also similar in both groups (2.2% and 2.3%, respectively; hazard ratio, 0.97; 95% confidence interval, 0.56 to 1.69; P=0.92). Consistent effects were observed in all subgroups analyzed, including those with renal impairment. CONCLUSIONS: In this large randomized trial, we found that acetylcysteine does not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients undergoing coronary and peripheral vascular angiography. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00736866.
Authors: Marc A Lazzaro; Roberta L Novakovic; Andrei V Alexandrov; Ziad Darkhabani; Randall C Edgell; Joey English; Donald Frei; Dara G Jamieson; Vallabh Janardhan; Nazli Janjua; Rashid M Janjua; Irene Katzan; Pooja Khatri; Jawad F Kirmani; David S Liebeskind; Italo Linfante; Thanh N Nguyen; Jeffrey L Saver; Lori Shutter; Andrew Xavier; Dileep Yavagal; Osama O Zaidat Journal: Neurology Date: 2012-09-25 Impact factor: 9.910
Authors: Markus Meyer; Stephen P Bell; Zengyi Chen; Iwan Nyotowidjojo; Richard R Lachapelle; Timothy F Christian; Pamela C Gibson; Friederike F Keating; Harold L Dauerman; Martin M LeWinter Journal: J Thromb Thrombolysis Date: 2013-11 Impact factor: 2.300
Authors: Jennifer S McDonald; Robert J McDonald; John C Lieske; Rickey E Carter; Richard W Katzberg; Eric E Williamson; David F Kallmes; David E Kallmes Journal: Mayo Clin Proc Date: 2015-08 Impact factor: 7.616